REGENERON PHARMACEUTICALS (REGN) Stock Earnings & Estimates
NASDAQ:REGN - US75886F1075 - Common Stock
587.65 USD
+15.27 (+2.67%)
589 USD
+1.35 (+0.23%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 12.173B -24.26% | 13.117B 7.76% | 14.202B 8.27% | 14.164B -0.27% | 14.868B 4.97% | 16.308B 9.69% | 17.422B 6.83% | 18.46B 5.96% | 19.265B 4.36% | 19.655B 2.02% | 19.386B -1.37% | |
| EBITDA YoY % growth | 5.335B -42.22% | 4.757B -10.85% | 4.701B -1.17% | 4.56B -3.00% | 5.286B 15.92% | 6.105B 15.49% | 6.591B 7.96% | 7.088B 7.54% | 7.419B 4.67% | 7.692B 3.68% | 6.845B -11.01% | |
| EBIT YoY % growth | 4.994B -44.18% | 4.336B -13.19% | 4.218B -2.71% | 4.273B 1.30% | 4.693B 9.83% | 5.655B 20.50% | 6.324B 11.83% | 6.931B 9.60% | 7.51B 8.35% | 7.673B 2.17% | 7.417B -3.34% | |
| Operating Margin | 41.03% | 33.05% | 29.70% | 30.17% | 31.56% | 34.68% | 36.30% | 37.55% | 38.98% | 39.04% | 38.26% | |
| EPS YoY % growth | 42.40 -40.60% | 43.78 3.25% | 45.64 4.25% | 39.96 -12.44% | 42.27 5.77% | 49.86 17.95% | 54.73 9.76% | 59.80 9.27% | 64.43 7.74% | 67.92 5.42% | 66.76 -1.71% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 9.88 -20.74% | 9.41 -22.05% | 9.82 19.50% | 12.04 -6.63% | 11.29 14.27% | 11.12 18.19% | 9.68 -1.45% | 14.80 22.97% | 11.96 6.02% | 11.96 7.59% |
| Revenue Q2Q % growth | 3.638B -2.22% | 3.681B -2.86% | 3.48B 14.89% | 3.794B 3.22% | 3.845B 5.69% | 3.887B 5.60% | 3.491B 0.32% | 4.021B 5.98% | 3.944B 2.57% | 3.998B 2.86% |
| EBITDA Q2Q % growth | 1.135B -28.71% | 1.067B -33.86% | 1.195B 63.50% | 1.549B 14.61% | 1.519B 33.83% | 1.429B 33.93% | 1.144B -4.27% | 1.695B 9.43% | 1.439B -5.27% | 1.433B 0.28% |
| EBIT Q2Q % growth | 1.108B -10.33% | 1.003B -11.26% | 1.085B 79.64% | 1.328B 21.89% | 1.268B 14.44% | 1.237B 23.33% | 1.015B -6.45% | 1.557B 17.24% | 1.315B 3.71% | 1.304B 5.42% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 12.89 11.51% | 8.61 | 4.28 | 49.77% |
| Q1 2025 Q2Q % growth | 8.22 -13.93% | 9.00 | -0.78 | -8.66% |
| Q4 2024 Q2Q % growth | 12.07 1.77% | 11.50 | 0.57 | 4.93% |
| Q3 2024 Q2Q % growth | 12.46 7.51% | 11.93 | 0.53 | 4.48% |
| Q2 2024 Q2Q % growth | 11.56 12.89% | 10.83 | 0.73 | 6.79% |
| Q1 2024 Q2Q % growth | 9.55 -5.35% | 10.29 | -0.74 | -7.23% |
| Q4 2023 Q2Q % growth | 11.86 -5.57% | 10.95 | 0.91 | 8.36% |
| Q3 2023 Q2Q % growth | 11.59 4.04% | 10.93 | 0.66 | 6.01% |
| Q2 2023 Q2Q % growth | 10.24 4.81% | 10.04 | 0.20 | 1.99% |
| Q1 2023 Q2Q % growth | 10.09 12.99% | 9.75 | 0.34 | 3.50% |
| Q4 2022 Q2Q % growth | 12.56 -41.09% | 10.23 | 2.33 | 22.77% |
| Q3 2022 Q2Q % growth | 11.14 -22.48% | 9.67 | 1.47 | 15.25% |
| Q2 2022 Q2Q % growth | 9.77 -62.13% | 9.02 | 0.75 | 8.33% |
| Q1 2022 Q2Q % growth | 8.93 -9.71% | 9.93 | -1.00 | -10.09% |
| Q4 2021 Q2Q % growth | 21.32 123.71% | 18.71 | 2.61 | 13.93% |
| Q3 2021 Q2Q % growth | 14.37 71.89% | 10.31 | 4.06 | 39.43% |
| Q2 2021 Q2Q % growth | 25.80 260.34% | 17.88 | 7.92 | 44.32% |
| Q1 2021 Q2Q % growth | 9.89 49.85% | 9.18 | 0.71 | 7.72% |
| Q4 2020 Q2Q % growth | 9.53 27.07% | 8.56 | 0.97 | 11.32% |
| Q3 2020 Q2Q % growth | 8.36 25.34% | 7.28 | 1.08 | 14.87% |
| Q2 2020 Q2Q % growth | 7.16 18.94% | 6.10 | 1.06 | 17.32% |
| Q1 2020 Q2Q % growth | 6.60 48.31% | 6.25 | 0.35 | 5.53% |
| Q4 2019 Q2Q % growth | 7.50 | 7.04 | 0.46 | 6.46% |
| Q3 2019 Q2Q % growth | 6.67 | 6.49 | 0.18 | 2.79% |
| Q2 2019 Q2Q % growth | 6.02 | 5.52 | 0.50 | 9.15% |
| Q1 2019 Q2Q % growth | 4.45 | 5.58 | -1.13 | -20.29% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 3.676B 3.62% | 3.35B | 325.6M | 9.72% |
| Q1 2025 Q2Q % growth | 3.029B -3.69% | 3.34B | -311M | -9.31% |
| Q4 2024 Q2Q % growth | 3.789B 10.34% | 3.824B | -34.8M | -0.91% |
| Q3 2024 Q2Q % growth | 3.721B 10.65% | 3.744B | -23.3M | -0.62% |
| Q2 2024 Q2Q % growth | 3.547B 12.32% | 3.446B | 101.1M | 2.93% |
| Q1 2024 Q2Q % growth | 3.145B -0.54% | 3.284B | -139M | -4.23% |
| Q4 2023 Q2Q % growth | 3.434B 0.57% | 3.351B | 83M | 2.48% |
| Q3 2023 Q2Q % growth | 3.363B 14.53% | 3.298B | 64.7M | 1.96% |
| Q2 2023 Q2Q % growth | 3.158B 10.53% | 3.077B | 81.1M | 2.64% |
| Q1 2023 Q2Q % growth | 3.162B 6.64% | 3.06B | 102.1M | 3.34% |
| Q4 2022 Q2Q % growth | 3.414B -31.05% | 3.188B | 226.4M | 7.10% |
| Q3 2022 Q2Q % growth | 2.936B -14.96% | 2.926B | 10.2M | 0.35% |
| Q2 2022 Q2Q % growth | 2.857B -44.40% | 2.852B | 5.2M | 0.18% |
| Q1 2022 Q2Q % growth | 2.965B 17.26% | 2.779B | 186.1M | 6.70% |
| Q4 2021 Q2Q % growth | 4.952B 104.37% | 4.598B | 353.7M | 7.69% |
| Q3 2021 Q2Q % growth | 3.453B 50.51% | 2.873B | 579.8M | 20.18% |
| Q2 2021 Q2Q % growth | 5.139B 163.24% | 3.995B | 1.144B | 28.62% |
| Q1 2021 Q2Q % growth | 2.529B 38.32% | 2.602B | -73.3M | -2.82% |
| Q4 2020 Q2Q % growth | 2.423B 11.68% | 2.471B | -48.1M | -1.95% |
| Q3 2020 Q2Q % growth | 2.294B 31.56% | 2.13B | 164M | 7.70% |
| Q2 2020 Q2Q % growth | 1.952B 23.72% | 1.777B | 175M | 9.85% |
| Q1 2020 Q2Q % growth | 1.828B 33.19% | 1.793B | 35.2M | 1.96% |
| Q4 2019 Q2Q % growth | 2.17B | 2.143B | 26.5M | 1.24% |
| Q3 2019 Q2Q % growth | 1.744B | 2.026B | -282.3M | -13.93% |
| Q2 2019 Q2Q % growth | 1.578B | 1.838B | -260.2M | -14.16% |
| Q1 2019 Q2Q % growth | 1.373B | 1.796B | -423.4M | -23.57% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 4.73% | -15.21% | 10.71% | 9.87% |
| Revenue | 4.15% | -4.24% | 3.78% | 3.68% |